Halozyme Therapeutics (HALO) PT Lowered to $19 at BMO Capital
BMO Capital analyst Do Kim lowered the price target on Halozyme Therapeutics (NASDAQ: HALO) to $19.00 (from $21.00) while maintaining ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
(Premium-only article. Please sign in or upgrade to SI Premium to view.)